Stamos Capital Partners L.P. Sells 19,510 Shares of Gilead Sciences, Inc. (NASDAQ:GILD)

Stamos Capital Partners L.P. decreased its holdings in shares of Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 59.2% in the 4th quarter, according to its most recent Form 13F filing with the SEC. The firm owned 13,450 shares of the biopharmaceutical company's stock after selling 19,510 shares during the period. Stamos Capital Partners L.P.'s holdings in Gilead Sciences were worth $1,242,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently made changes to their positions in GILD. Westside Investment Management Inc. increased its stake in Gilead Sciences by 3.5% in the 3rd quarter. Westside Investment Management Inc. now owns 27,443 shares of the biopharmaceutical company's stock valued at $2,249,000 after buying an additional 917 shares during the period. SkyView Investment Advisors LLC boosted its holdings in shares of Gilead Sciences by 5.4% in the third quarter. SkyView Investment Advisors LLC now owns 8,482 shares of the biopharmaceutical company's stock valued at $711,000 after acquiring an additional 435 shares in the last quarter. Pine Valley Investments Ltd Liability Co acquired a new position in Gilead Sciences during the 3rd quarter worth approximately $209,000. World Investment Advisors LLC raised its position in Gilead Sciences by 33.6% in the third quarter. World Investment Advisors LLC now owns 25,999 shares of the biopharmaceutical company's stock worth $2,180,000 after acquiring an additional 6,535 shares in the last quarter. Finally, Arvest Bank Trust Division acquired a new stake in shares of Gilead Sciences in the third quarter valued at about $9,661,000. Hedge funds and other institutional investors own 83.67% of the company's stock.

Remove Ads

Insider Buying and Selling at Gilead Sciences

In other news, CFO Andrew D. Dickinson sold 2,500 shares of the firm's stock in a transaction dated Tuesday, April 15th. The stock was sold at an average price of $106.40, for a total transaction of $266,000.00. Following the completion of the sale, the chief financial officer now directly owns 168,174 shares of the company's stock, valued at $17,893,713.60. This trade represents a 1.46 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Over the last 90 days, insiders have sold 302,785 shares of company stock valued at $30,540,875. Corporate insiders own 0.16% of the company's stock.

Analysts Set New Price Targets

Several research firms have weighed in on GILD. Morgan Stanley upped their target price on Gilead Sciences from $123.00 to $130.00 and gave the company an "overweight" rating in a report on Tuesday, March 11th. Royal Bank of Canada boosted their price target on Gilead Sciences from $84.00 to $90.00 and gave the stock a "sector perform" rating in a report on Wednesday, February 12th. Deutsche Bank Aktiengesellschaft raised shares of Gilead Sciences from a "hold" rating to a "buy" rating and boosted their price objective for the company from $80.00 to $120.00 in a research report on Tuesday, February 18th. Bank of America increased their price objective on shares of Gilead Sciences from $116.00 to $126.00 and gave the stock a "buy" rating in a report on Wednesday, March 5th. Finally, Needham & Company LLC reaffirmed a "hold" rating on shares of Gilead Sciences in a research note on Wednesday, February 12th. Eleven analysts have rated the stock with a hold rating, fifteen have issued a buy rating and four have assigned a strong buy rating to the company's stock. Based on data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and a consensus target price of $105.12.

Gilead Sciences Stock Performance

Shares of GILD traded down $0.80 during midday trading on Wednesday, hitting $104.88. 7,115,838 shares of the stock traded hands, compared to its average volume of 7,504,431. The business's 50 day moving average price is $108.63 and its two-hundred day moving average price is $97.11. The firm has a market capitalization of $130.59 billion, a PE ratio of 283.46, a price-to-earnings-growth ratio of 0.71 and a beta of 0.32. The company has a debt-to-equity ratio of 1.24, a quick ratio of 1.20 and a current ratio of 1.50. Gilead Sciences, Inc. has a 1-year low of $62.07 and a 1-year high of $119.96.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last posted its earnings results on Tuesday, February 11th. The biopharmaceutical company reported $1.90 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.67 by $0.23. Gilead Sciences had a net margin of 1.67% and a return on equity of 31.63%. Equities research analysts predict that Gilead Sciences, Inc. will post 7.95 EPS for the current fiscal year.

Gilead Sciences Increases Dividend

The company also recently declared a quarterly dividend, which was paid on Friday, March 28th. Stockholders of record on Friday, March 14th were given a dividend of $0.79 per share. The ex-dividend date was Friday, March 14th. This is a boost from Gilead Sciences's previous quarterly dividend of $0.77. This represents a $3.16 annualized dividend and a dividend yield of 3.01%. Gilead Sciences's dividend payout ratio (DPR) is 854.05%.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.